Clinical trial • Phase III • Haematology

TECLISTAMAB for Multiple myeloma

Phase III trial of TECLISTAMAB for Multiple myeloma.

Overview

Trial Therapeutic Area
Haematology
Trial Disease
Multiple myeloma
Trial Stage
Phase III
Drug Modality
Bispecific antibody|Monoclonal antibody|Small molecule|Peptide/protein/enzyme
Orphan Drug
Yes

Key dates

Initial CTIS Submission Date
27-06-2024
First CTIS Authorization Date
26-08-2024

Trial design

Randomised, daratumumab subcutaneous + lenalidomide + dexamethasone (drd); specific doses and schedule not specified in the ctis summary-controlled Phase III trial in Italy, Austria, Netherlands and others.

Randomised
Yes
Comparator
Daratumumab subcutaneous + Lenalidomide + Dexamethasone (DRd); specific doses and schedule not specified in the CTIS summary
Target Sample Size
937

Eligibility

Recruits 937 adults.

Pregnancy Exclusion
A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment

Inclusion criteria

  • {"criterion_text":"- Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria\n- Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment\n- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2\n- A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment\n- A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment"}

Exclusion criteria

  • {"criterion_text":"- Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 mg dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (≥)20 mg of dexamethasone within 14 days before Randomization.\n- Had plasmapheresis within 28 days of randomization\n- Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization\n- Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients\n- Known contraindications to the use of daratumumab or lenalidomide per local prescribing information\n- Myeloma Frailty Index of ≥2 with the exception of participants who have a score of 2 based on age alone"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Dual primary endpoints: PFS; 12-month MRD-negative CR","definition_or_measurement_approach":""}

Recruitment

Planned Sample Size
937
Recruitment Window Months
129
Consent Approach
Informed consent documents (subject information and informed consent forms) are provided as country-specific ICFs. Multiple country/language versions are available (examples seen in CTIS documents: English, Italian, German, Dutch, Polish, Norwegian, Swedish, French, Czech, Spanish, Portuguese). ICFs and related documents (withdrawal forms, pregnant partner/patient information, subject wallet cards) are provided by the sponsor per country. No specific pediatric assent forms are listed in the public CTIS documents.

Geography

Total Number Of Sites
90
Total Number Of Participants
568

Italy

Earliest CTIS Part Ii Submission Date
16-07-2024
Latest Decision Or Authorization Date
02-09-2024
Processing Time Days
48
Number Of Sites
9
Number Of Participants
50

Sites

Site Name
Humanitas Mirasole S.p.A.
Department Name
UOC Ematologia - Building 2, 3° piano
Principal Investigator Name
Rita Mazza
Principal Investigator Email
rita.mazza@cancercenter.humanitas.it
Contact Person Name
Rita Mazza
Site Name
Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
Department Name
UOC Ematologia
Principal Investigator Name
Alessandra Larocca
Principal Investigator Email
alessandra.larocca@unito.it
Contact Person Name
Alessandra Larocca
Contact Person Email
alessandra.larocca@unito.it
Site Name
Careggi University Hospital
Department Name
SOD Ematologia
Principal Investigator Name
Elisabetta Antonioli
Principal Investigator Email
antoniolie@aou-careggi.toscana.it
Contact Person Name
Elisabetta Antonioli
Site Name
Azienda Ospedaliera Di Rilievo Nazionale Antonio Cardarelli
Department Name
UO Ematologia con TMO
Principal Investigator Name
Salvatore Palmieri
Principal Investigator Email
salvatore.palmieri@aocardarelli.it
Contact Person Name
Salvatore Palmieri
Site Name
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Department Name
Dipartimento Malattie Oncologiche ed Ematologiche
Principal Investigator Name
Elena Zamagni
Principal Investigator Email
e.zamagni@unibo.it
Contact Person Name
Elena Zamagni
Contact Person Email
e.zamagni@unibo.it
Site Name
Fondazione IRCCS Policlinico San Matteo
Department Name
SC Ematologia 1
Principal Investigator Name
Silvia Mangiacavalli
Principal Investigator Email
silvia_mangiacavalli@hotmail.com
Contact Person Name
Silvia Mangiacavalli
Site Name
Azienda Ospedaliera Policlinico Universitario Tor Vergata
Department Name
UOC Patologie Linfoproliferatve
Principal Investigator Name
Luca Franceschini
Principal Investigator Email
luca.franceschini@ptvonline.it
Contact Person Name
Luca Franceschini
Contact Person Email
luca.franceschini@ptvonline.it
Site Name
Ospedale San Raffaele S.r.l.
Department Name
UO Ematologia - TMO
Principal Investigator Name
Valeria Ferla
Principal Investigator Email
FERLA.VALERIA@hsr.it
Contact Person Name
Valeria Ferla
Contact Person Email
FERLA.VALERIA@hsr.it
Site Name
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
Department Name
UOC Ematologia
Principal Investigator Name
Monica Galli
Principal Investigator Email
monicagalli@asst-pg23.it
Contact Person Name
Monica Galli
Contact Person Email
monicagalli@asst-pg23.it

Austria

Earliest CTIS Part Ii Submission Date
16-07-2024
Latest Decision Or Authorization Date
02-09-2024
Processing Time Days
48
Number Of Sites
4
Number Of Participants
15

Sites

Site Name
SCRI CCCIT Ges.m.b.H.
Department Name
3rd Med. Depart. Hematology, Med. Oncology, Hemostaseology, Infectious Disease and Rheumatology
Principal Investigator Name
Thomas Melchardt
Principal Investigator Email
t.melchardt@salk.at
Contact Person Name
Thomas Melchardt
Contact Person Email
t.melchardt@salk.at
Site Name
Medical University Of Vienna
Department Name
Univ. clinic for Internal Medicine I, Department of hematology und hemostaseology
Principal Investigator Name
Maria-Theresia Krauth
Principal Investigator Email
maria.krauth@meduniwien.ac.at
Contact Person Name
Maria-Theresia Krauth
Contact Person Email
maria.krauth@meduniwien.ac.at
Site Name
Hanusch Krankenhaus Der Wiener Gebietskrankenkasse
Department Name
3. Medical department – Department of hematology & Oncology
Principal Investigator Name
Agnes List
Principal Investigator Email
agnes.list@oegk.at
Contact Person Name
Agnes List
Contact Person Email
agnes.list@oegk.at
Site Name
Ordensklinikum Linz GmbH
Department Name
Internal 1 - Hematology with stem cell transplantation, hemostaseology and medical oncology
Principal Investigator Name
Irene Strassl
Principal Investigator Email
irene.strassl@ordensklinikum.at
Contact Person Name
Irene Strassl

Netherlands

Earliest CTIS Part Ii Submission Date
16-07-2024
Latest Decision Or Authorization Date
27-08-2024
Processing Time Days
42
Number Of Sites
5
Number Of Participants
30

Sites

Site Name
St. Antonius Ziekenhuis
Department Name
Hematologie
Principal Investigator Name
Inger Nijhof
Principal Investigator Email
i.nijhof@antoniusziekenhuis.nl
Contact Person Name
Inger Nijhof
Contact Person Email
i.nijhof@antoniusziekenhuis.nl
Site Name
Reinier de Graaf Groep
Department Name
Hematologie
Principal Investigator Name
Savita Soechit
Principal Investigator Email
s.soechit@rdgg.nl
Contact Person Name
Savita Soechit
Contact Person Email
s.soechit@rdgg.nl
Site Name
Gelre Hospitals
Department Name
Hematologie
Principal Investigator Name
Cees Schaar
Principal Investigator Email
c.schaar@gelre.nl
Contact Person Name
Cees Schaar
Contact Person Email
c.schaar@gelre.nl
Site Name
Amsterdam UMC Stichting
Department Name
Hematologie
Principal Investigator Name
Niels van de Donk
Principal Investigator Email
n.vandedonk@amsterdamumc.nl
Contact Person Name
Niels van de Donk
Contact Person Email
n.vandedonk@amsterdamumc.nl
Site Name
Zuyderland Medisch Centrum Stichting
Department Name
Hematologie
Principal Investigator Name
Roel Van Kampen
Principal Investigator Email
r.vankampen@zuyderland.nl
Contact Person Name
Roel Van Kampen
Contact Person Email
r.vankampen@zuyderland.nl

Poland

Earliest CTIS Part Ii Submission Date
16-07-2024
Latest Decision Or Authorization Date
29-08-2024
Processing Time Days
44
Number Of Sites
9
Number Of Participants
80

Sites

Site Name
Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy
Department Name
Klinika Hematologii
Principal Investigator Name
Marta Sobas
Principal Investigator Email
marta.sobas@biziel.pl
Contact Person Name
Marta Sobas
Contact Person Email
marta.sobas@biziel.pl
Site Name
Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Kielcach
Department Name
Klinika Hematologii i Transplantacji Szpiku
Principal Investigator Name
Pawel Steckiewicz
Principal Investigator Email
p.steckiewicz@gmail.com
Contact Person Name
Pawel Steckiewicz
Contact Person Email
p.steckiewicz@gmail.com
Site Name
Centrum Onkologii Ziemi Lubelskiej Im. Sw. Jana Z Dukli
Principal Investigator Name
Wojciech Legiec
Principal Investigator Email
legiec.wojciech@gmail.com
Contact Person Name
Wojciech Legiec
Contact Person Email
legiec.wojciech@gmail.com
Site Name
Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M.Kopernika W Lodzi
Department Name
Oddzial Hematologii z Pododdzialem Chemioterapii - Klinika Hematologii
Principal Investigator Name
Joanna Gora-Tybor
Principal Investigator Email
joannagora@op.pl
Contact Person Name
Joanna Gora-Tybor
Contact Person Email
joannagora@op.pl
Site Name
Uniwersytecki Szpital Kliniczny Nr 1 W Lublinie
Department Name
Katedra i Klinika Hematologii i Transplantacji Szpiku
Principal Investigator Name
Marek Hus
Principal Investigator Email
markhus@o2.pl
Contact Person Name
Marek Hus
Contact Person Email
markhus@o2.pl
Site Name
Uniwersytecki Szpital Kliniczny W Poznaniu
Department Name
Oddzial Hematologii I Transplantacji Szpiku
Principal Investigator Name
Dominik Dytfeld
Principal Investigator Email
dytfeld@me.com
Contact Person Name
Dominik Dytfeld
Contact Person Email
dytfeld@me.com
Site Name
Pratia Hematologia Sp. z o.o.
Department Name
Pratia Onkologia Katowice
Principal Investigator Name
Sebastian Grosicki
Principal Investigator Email
sgrosicki@wp.pl
Contact Person Name
Sebastian Grosicki
Contact Person Email
sgrosicki@wp.pl
Site Name
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
Department Name
Katedra I Klinika Hematologii, Transplantologii I Chorob Wewnetrznych
Principal Investigator Name
Krzysztof Jamroziak
Principal Investigator Email
k.m.jamroziak@gmail.com
Contact Person Name
Krzysztof Jamroziak
Contact Person Email
k.m.jamroziak@gmail.com
Site Name
Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza
Principal Investigator Name
Jacek Krzanowski
Principal Investigator Email
jacek.krzanowski@gmail.com
Contact Person Name
Jacek Krzanowski
Contact Person Email
jacek.krzanowski@gmail.com

Norway

Earliest CTIS Part Ii Submission Date
31-07-2024
Latest Decision Or Authorization Date
26-08-2024
Processing Time Days
26
Number Of Sites
2
Number Of Participants
20

Sites

Site Name
Oslo University Hospital HF
Department Name
OMC
Principal Investigator Name
Fredrik Shjesvold
Principal Investigator Email
fredrikschjesvold@gmail.com
Contact Person Name
Fredrik Shjesvold
Contact Person Email
fredrikschjesvold@gmail.com
Site Name
St. Olavs Hospital HF
Department Name
Of hematology
Principal Investigator Name
Tobias S. Slørdahl
Principal Investigator Email
tobias.s.slordahl@ntnu.no
Contact Person Name
Tobias S. Slørdahl
Contact Person Email
tobias.s.slordahl@ntnu.no

Sweden

Earliest CTIS Part Ii Submission Date
16-07-2024
Latest Decision Or Authorization Date
29-08-2024
Processing Time Days
44
Number Of Sites
4
Number Of Participants
16

Sites

Site Name
Region Oerebro Laen
Department Name
Medicinmottagning 2
Principal Investigator Name
Jacob Crafoord
Principal Investigator Email
jacob.crafoord@regionorebrolan.se
Contact Person Name
Jacob Crafoord
Site Name
Region Skane Skanes Universitetssjukhus
Department Name
Hematologimottagning
Principal Investigator Name
Konstantinos Lemonakis
Principal Investigator Email
konstantinos.lemonakis@skane.se
Contact Person Name
Konstantinos Lemonakis
Site Name
Karolinska University Hospital
Department Name
Hematologiskt centrum
Principal Investigator Name
Katarina Uttervall
Principal Investigator Email
katarina.uttervall@regionstockholm.se
Contact Person Name
Katarina Uttervall
Site Name
Region Dalarna
Department Name
Medicinkliniken Hematologimottagningen
Principal Investigator Name
Max Flogegard
Principal Investigator Email
max.flogegard@regiondalarna.se
Contact Person Name
Max Flogegard
Contact Person Email
max.flogegard@regiondalarna.se

Denmark

Earliest CTIS Part Ii Submission Date
16-07-2024
Latest Decision Or Authorization Date
26-08-2024
Processing Time Days
41
Number Of Sites
4
Number Of Participants
15

Sites

Site Name
Sygehus Lillebaelt Vejle Sygehus
Department Name
Department Of Hematology
Principal Investigator Name
Sarah Farmer
Principal Investigator Email
Sarah.Farmer1@rsyd.dk
Contact Person Name
Sarah Farmer
Contact Person Email
Sarah.Farmer1@rsyd.dk
Site Name
Næstved Hospital
Department Name
Haematologisk Administrationsgang
Principal Investigator Name
Trung Hieu Do
Principal Investigator Email
trhd@regionsjaelland.dk
Contact Person Name
Trung Hieu Do
Contact Person Email
trhd@regionsjaelland.dk
Site Name
Region Midtjylland
Department Name
Klinik for Blodsygdomme
Principal Investigator Name
Robert Schou Pedersen
Principal Investigator Email
Robert.Schou.Pedersen@goedstrup.rm.dk
Contact Person Name
Robert Schou Pedersen
Site Name
Aalborg University Hospital
Department Name
Department of Hematology
Principal Investigator Name
Henrik Gregersen
Principal Investigator Email
henrik.gregersen@rn.dk
Contact Person Name
Henrik Gregersen
Contact Person Email
henrik.gregersen@rn.dk

Belgium

Earliest CTIS Part Ii Submission Date
16-07-2024
Latest Decision Or Authorization Date
26-08-2024
Processing Time Days
41
Number Of Sites
5
Number Of Participants
30

Sites

Site Name
Algemeen Ziekenhuis Groeninge
Department Name
Hemotologie
Principal Investigator Name
Koen Maes
Principal Investigator Email
koen.maes@azgroeninge.be
Contact Person Name
Koen Maes
Contact Person Email
koen.maes@azgroeninge.be
Site Name
Universitair Ziekenhuis Gent
Department Name
Hematologie
Principal Investigator Name
Nicolas Kint
Principal Investigator Email
Nicolas.kint@uzgent.be
Contact Person Name
Nicolas Kint
Contact Person Email
Nicolas.kint@uzgent.be
Site Name
Ziekenhuis Aan De Stroom
Department Name
Hematologie
Principal Investigator Name
Ka Lung Wu
Principal Investigator Email
kalung.wu@zas.be
Contact Person Name
Ka Lung Wu
Contact Person Email
kalung.wu@zas.be
Site Name
UZ Leuven
Department Name
Hematologie
Principal Investigator Name
Michel Delforge
Principal Investigator Email
michel.delforge@uzleuven.be
Contact Person Name
Michel Delforge
Contact Person Email
michel.delforge@uzleuven.be
Site Name
Institut Jules Bordet
Department Name
Hématologie
Principal Investigator Name
Nathalie Meuleman
Principal Investigator Email
nathalie.meuleman@hubruxelles.be
Contact Person Name
Nathalie Meuleman

France

Earliest CTIS Part Ii Submission Date
16-07-2024
Latest Decision Or Authorization Date
30-08-2024
Processing Time Days
45
Number Of Sites
12
Number Of Participants
70

Sites

Site Name
Centre Hospitalier Universitaire De Toulouse
Department Name
Hématologie
Principal Investigator Name
Aurore PERROT
Principal Investigator Email
perrot.aurore@iuct-oncopole.fr
Contact Person Name
Aurore PERROT
Contact Person Email
perrot.aurore@iuct-oncopole.fr
Site Name
Centre Hospitalier Universitaire De Bordeaux
Department Name
Hématologie clinique et de Thérapie cellulaire
Principal Investigator Name
Cyrille HULIN
Principal Investigator Email
cyrille.hulin@chu-bordeaux.fr
Contact Person Name
Cyrille HULIN
Contact Person Email
cyrille.hulin@chu-bordeaux.fr
Site Name
Centre Hospitalier Universitaire De Nantes
Department Name
Hématologie Clinique
Principal Investigator Name
Cyrille TOUZEAU
Principal Investigator Email
Cyrille.TOUZEAU@chu-nantes.fr
Contact Person Name
Cyrille TOUZEAU
Contact Person Email
Cyrille.TOUZEAU@chu-nantes.fr
Site Name
Les Hopitaux Universitaires De Strasbourg
Department Name
Oncology and Hematology
Principal Investigator Name
Cecile SONNTAG
Principal Investigator Email
c.sonntag@icans.eu
Contact Person Name
Cecile SONNTAG
Contact Person Email
c.sonntag@icans.eu
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Hématologie et Thérapie cellulaire
Principal Investigator Name
MOHAMAD MOHTY
Principal Investigator Email
hematosa.urcest.sat@aphp.fr
Contact Person Name
MOHAMAD MOHTY
Contact Person Email
hematosa.urcest.sat@aphp.fr
Site Name
Institut De Cancerologie Strasbourg Europe
Department Name
Hématologie
Principal Investigator Name
Cecile SONNTAG
Principal Investigator Email
c.sonntag@icans.eu
Contact Person Name
Cecile SONNTAG
Contact Person Email
c.sonntag@icans.eu
Site Name
Centre Hospitalier Universitaire De Dijon
Department Name
Hématologie Clinique
Principal Investigator Name
Jean-noel BASTIE
Principal Investigator Email
jean-noel.bastie@chu-dijon.fr
Contact Person Name
Jean-noel BASTIE
Contact Person Email
jean-noel.bastie@chu-dijon.fr
Site Name
Hospices Civils De Lyon
Department Name
Hématologie Clinique
Principal Investigator Name
Lionel KARLIN
Principal Investigator Email
lionel.karlin@chu-lyon.fr
Contact Person Name
Lionel KARLIN
Contact Person Email
lionel.karlin@chu-lyon.fr
Site Name
Centre Hospitalier Universitaire De Poitiers
Department Name
Hématologie et Thérapie cellulaire
Principal Investigator Name
Xavier LELEU
Principal Investigator Email
xavier.leleu@chu-poitiers.fr
Contact Person Name
Xavier LELEU
Contact Person Email
xavier.leleu@chu-poitiers.fr
Site Name
Assistance Publique Hopitaux De Paris (Creteil)
Department Name
Hémopathies Lymphoïdes
Principal Investigator Name
Karim BELHADJ-MERZOUG
Principal Investigator Email
karim.belhadj@aphp.fr
Contact Person Name
Karim BELHADJ-MERZOUG
Contact Person Email
karim.belhadj@aphp.fr
Site Name
Centre Hospitalier Universitaire De Rennes
Department Name
Hématologie
Principal Investigator Name
Olivier DECAUX
Principal Investigator Email
Olivier.Decaux@chu-rennes.fr
Contact Person Name
Olivier DECAUX
Contact Person Email
Olivier.Decaux@chu-rennes.fr
Site Name
Centre Hospitalier Universitaire De Lille
Department Name
Hématologie
Principal Investigator Name
Salomon MANIER
Principal Investigator Email
salomon.manier@chru-lille.fr
Contact Person Name
Salomon MANIER
Contact Person Email
salomon.manier@chru-lille.fr

Greece

Earliest CTIS Part Ii Submission Date
11-09-2024
Latest Decision Or Authorization Date
18-10-2024
Processing Time Days
37
Number Of Sites
3
Number Of Participants
23

Sites

Site Name
Theageneio Cancer Hospital
Department Name
Hematology Clinic
Principal Investigator Name
Eirini Katodritou
Principal Investigator Email
eirinikatodritou@gmail.com
Contact Person Name
Eirini Katodritou
Contact Person Email
eirinikatodritou@gmail.com
Site Name
Alexandra Hospital
Department Name
Therapeutic Clinic-Oncology Department
Principal Investigator Name
Meletios-Athanasios Dimopoulos
Principal Investigator Email
mdimop@med.uoa.gr
Contact Person Name
Meletios-Athanasios Dimopoulos
Contact Person Email
mdimop@med.uoa.gr
Site Name
Geniko Nosokomeio Thessalonikis George Papanikolaou
Department Name
Hematology Department and Bone Marrow Transplantation Unit
Principal Investigator Name
Michail Iskas
Principal Investigator Email
michail.iskas@gpapanikolaou.gr
Contact Person Name
Michail Iskas
Contact Person Email
michail.iskas@gpapanikolaou.gr

Germany

Earliest CTIS Part Ii Submission Date
16-07-2024
Latest Decision Or Authorization Date
28-08-2024
Processing Time Days
43
Number Of Sites
8
Number Of Participants
46

Sites

Site Name
Universitaetsklinikum Essen AöR
Department Name
Klinik für Hämatologie und Stammzelltransplantation
Principal Investigator Name
Amelie Boquoi
Principal Investigator Email
amelie.boquoi@uk-essen.de
Contact Person Name
Amelie Boquoi
Contact Person Email
amelie.boquoi@uk-essen.de
Site Name
Klinikum Nuernberg
Department Name
Klinik fuer Innere Medizin 5, Schwerpunkt Onkologie/Haematologie
Principal Investigator Name
Stefan Knop
Principal Investigator Email
stefan.knop@klinikum-nuernberg.de
Contact Person Name
Stefan Knop
Site Name
Martin-Luther-Universitaet Halle-Wittenberg
Department Name
Abt. Haematologie/Onkologie
Principal Investigator Name
Franziska Brunner
Principal Investigator Email
franziska.brunner@uk-halle.de
Contact Person Name
Franziska Brunner
Contact Person Email
franziska.brunner@uk-halle.de
Site Name
Universitaetsklinikum Wuerzburg AöR
Department Name
Med. Klinik und Poliklinik II, Abteilung fur Onkologie/Haematologie
Principal Investigator Name
Martin Kortuem
Principal Investigator Email
kortuem_m@ukw.de
Contact Person Name
Martin Kortuem
Contact Person Email
kortuem_m@ukw.de
Site Name
University Medical Center Hamburg-Eppendorf
Department Name
II. Med. Klinik und Poliklinik, Haematologie u. Onkologie
Principal Investigator Name
Katja Weisel
Principal Investigator Email
k.weisel@uke.de
Contact Person Name
Katja Weisel
Contact Person Email
k.weisel@uke.de
Site Name
Universitaetsklinikum Tuebingen AöR
Department Name
Abteilung fur Innere Medizin II, Hamatologie, Onkologie Rheumatololgie
Principal Investigator Name
Britta Besemer
Principal Investigator Email
britta.besemer@med.uni-tuebingen.de
Contact Person Name
Britta Besemer
Site Name
HELIOS Klinikum Berlin-Buch GmbH
Department Name
Klinik Fuer Haematologie Onkologie Und Turmorimmunologie
Principal Investigator Name
Snjezana Janjetovic
Principal Investigator Email
Snjezana.Janjetovic@helios-gesundheit.de
Contact Person Name
Snjezana Janjetovic
Site Name
Klinikum Nuernberg (additional listed site)
Department Name
Klinik fuer Innere Medizin 5, Schwerpunkt Onkologie/Haematologie

Czechia

Earliest CTIS Part Ii Submission Date
16-07-2024
Latest Decision Or Authorization Date
30-08-2024
Processing Time Days
45
Number Of Sites
6
Number Of Participants
42

Sites

Site Name
Fakultni Nemocnice Brno
Department Name
Interni hematologicka a onkologicka klinika
Principal Investigator Name
Ludek Pour
Principal Investigator Email
pour.ludek@fnbrno.cz
Contact Person Name
Ludek Pour
Contact Person Email
pour.ludek@fnbrno.cz
Site Name
Fakultni Nemocnice Ostrava
Department Name
Klinika hematoonkologie
Principal Investigator Name
Roman Hajek
Principal Investigator Email
roman.hajek@fno.cz
Contact Person Name
Roman Hajek
Contact Person Email
roman.hajek@fno.cz
Site Name
Vseobecna Fakultni Nemocnice V Praze
Department Name
I. interni klinika- klinika hematologie
Principal Investigator Name
Ivan Spicka
Principal Investigator Email
spicka@cesnet.cz
Contact Person Name
Ivan Spicka
Contact Person Email
spicka@cesnet.cz
Site Name
University Hospital Olomouc
Department Name
Hemato-onkologicka klinika
Principal Investigator Name
Jiri Minarik
Principal Investigator Email
abretina@email.cz
Contact Person Name
Jiri Minarik
Contact Person Email
abretina@email.cz
Site Name
Fakultni Nemocnice Plzen
Department Name
Hemato-onkologicke oddeleni
Principal Investigator Name
Alexandra Jungova
Principal Investigator Email
jungovaa@fnplzen.cz
Contact Person Name
Alexandra Jungova
Contact Person Email
jungovaa@fnplzen.cz
Site Name
Fakultni Nemocnice Hradec Kralove
Department Name
IV.interni hematologicka klinika
Principal Investigator Name
Jakub Radocha
Principal Investigator Email
jakub.radocha@centrum.cz
Contact Person Name
Jakub Radocha
Contact Person Email
jakub.radocha@centrum.cz

Spain

Earliest CTIS Part Ii Submission Date
16-07-2024
Latest Decision Or Authorization Date
27-08-2024
Processing Time Days
42
Number Of Sites
14
Number Of Participants
100

Sites

Site Name
Hospital Universitario Quironsalud Madrid
Department Name
Hematology
Principal Investigator Name
Carmen Martinez-Chamorro
Principal Investigator Email
mcarmen.chamorro@quironsalud.es
Contact Person Name
Carmen Martinez-Chamorro
Site Name
Institut Catala D'oncologia
Department Name
Hematology
Principal Investigator Name
Laura Abril Sabater
Principal Investigator Email
labril@iconcologia.net
Contact Person Name
Laura Abril Sabater
Contact Person Email
labril@iconcologia.net
Site Name
Fundacio Assistencial De Mutua De Terrassa Fpc
Department Name
Hematology
Principal Investigator Name
Josep María Marti Tutusaus
Principal Investigator Email
jmarti@mutuaterrassa.es
Contact Person Name
Josep María Marti Tutusaus
Contact Person Email
jmarti@mutuaterrassa.es
Site Name
Hospital Universitario La Paz
Department Name
Hematology
Principal Investigator Name
Teresa De Soto Álvarez
Principal Investigator Email
desoto.teresa@gmail.com
Contact Person Name
Teresa De Soto Álvarez
Contact Person Email
desoto.teresa@gmail.com
Site Name
Hospital De Jerez De La Frontera
Department Name
Hematology
Principal Investigator Name
Sebastian Garzón López
Principal Investigator Email
sebastianf.garzon.sspa@juntadeandalucia.es
Contact Person Name
Sebastian Garzón López
Site Name
Hospital Universitari Vall D Hebron
Department Name
Hematology
Principal Investigator Name
Mercedes Gironella Mesa
Principal Investigator Email
mgironella@vhio.net
Contact Person Name
Mercedes Gironella Mesa
Contact Person Email
mgironella@vhio.net
Site Name
Institut Catala D'oncologia (L'hospitalet)
Department Name
Hematology
Principal Investigator Name
Anna Sureda Balari
Principal Investigator Email
asureda@iconcologia.net
Contact Person Name
Anna Sureda Balari
Contact Person Email
asureda@iconcologia.net
Site Name
University Hospital Son Espases
Department Name
Hematology
Principal Investigator Name
Antonia Sampol Mayol
Principal Investigator Email
antonia.sampolm@ssib.es
Contact Person Name
Antonia Sampol Mayol
Contact Person Email
antonia.sampolm@ssib.es
Site Name
Hospital Universitario 12 De Octubre
Department Name
Hematology
Principal Investigator Name
Joaquin Martinez López
Principal Investigator Email
jmarti01@med.ucm.es
Contact Person Name
Joaquin Martinez López
Contact Person Email
jmarti01@med.ucm.es
Site Name
Hospital De La Santa Creu I Sant Pau
Department Name
Hematlogy
Principal Investigator Name
Jordi López Pardo
Principal Investigator Email
jlopezpar@santpau.cat
Contact Person Name
Jordi López Pardo
Contact Person Email
jlopezpar@santpau.cat
Site Name
Hospital Universitario Virgen De Las Nieves
Department Name
Hematology
Principal Investigator Name
Esther Clavero Sanchez
Principal Investigator Email
eclaverosa@hotmail.com
Contact Person Name
Esther Clavero Sanchez
Contact Person Email
eclaverosa@hotmail.com
Site Name
Hospital Universitario Hm Sanchinarro
Department Name
Hematology
Principal Investigator Name
Felipe Casado Montero
Principal Investigator Email
lfcasado@hmhospitales.com
Contact Person Name
Felipe Casado Montero
Contact Person Email
lfcasado@hmhospitales.com
Site Name
Hospital Universitario De Salamanca
Department Name
Hematology clinical trials
Principal Investigator Name
Maria Victoria Mateos Manteca
Principal Investigator Email
mvmateos@usal.es
Contact Person Name
Maria Victoria Mateos Manteca
Contact Person Email
mvmateos@usal.es
Site Name
Hospital Clinico Universitario De Valencia
Department Name
Hematology
Principal Investigator Name
Ana Isabel Teruel Casasús
Principal Investigator Email
ateruelc@hotmail.com
Contact Person Name
Ana Isabel Teruel Casasús
Contact Person Email
ateruelc@hotmail.com

Portugal

Earliest CTIS Part Ii Submission Date
16-07-2024
Latest Decision Or Authorization Date
27-08-2024
Processing Time Days
42
Number Of Sites
5
Number Of Participants
31

Sites

Site Name
Champalimaud Clinical Centre
Department Name
Unidade de Hemato-Oncologia
Principal Investigator Name
Paulo Lúcio
Principal Investigator Email
paulo.lucio@fundacaochampalimaud.pt
Contact Person Name
Paulo Lúcio
Site Name
CCAB Centro Clinico Academico Braga Associacao
Department Name
Serviço de Oncologia Médica
Principal Investigator Name
José Freitas
Principal Investigator Email
jose.p.freitas@hb.min-saude.pt
Contact Person Name
José Freitas
Contact Person Email
jose.p.freitas@hb.min-saude.pt
Site Name
Unidade Local De Saude De Almada-Seixal E.P.E.
Department Name
Serviço de Hematologia
Principal Investigator Name
Sara Valle
Principal Investigator Email
sara.valle@ulsas.pt
Contact Person Name
Sara Valle
Contact Person Email
sara.valle@ulsas.pt
Site Name
University Of Porto
Department Name
Serviço de Hematologia Clínica
Principal Investigator Name
Rui Bergantim
Principal Investigator Email
rui.bergantim@chsj.min-saude.pt
Contact Person Name
Rui Bergantim
Site Name
Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.
Department Name
Serviço de Hematologia e Transplantação de Medula Óssea
Principal Investigator Name
Luisa Viterbo
Principal Investigator Email
lviterbo@ipoporto.min-saude.pt
Contact Person Name
Luisa Viterbo
Contact Person Email
lviterbo@ipoporto.min-saude.pt

Sponsor

Primary sponsor

Full Name
Janssen - Cilag International
Organisation Type
Pharmaceutical company
Country Of Registered Address
Belgium

Contract research organisations

Name
Parexel International Co. Ltd.
Responsibilities
code 6
Name
Almac Clinical Technologies LLC
Responsibilities
code 3

Third parties

  • {"country":"United States","full_name":"Hematogenix Laboratory Services LLC","duties_or_roles":"code 4","organisation_type":"Laboratory/Research/Testing facility"}
  • {"country":"United States","full_name":"Yprime LLC","duties_or_roles":"code 7","organisation_type":"Non-Pharmaceutical company"}
  • {"country":"United States","full_name":"Almac Clinical Technologies LLC","duties_or_roles":"code 3","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Adaptive Biotechnologies Corp.","duties_or_roles":"code 4","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Labcorp Central Laboratory Services LP","duties_or_roles":"code 4","organisation_type":"Pharmaceutical company"}
  • {"country":"Taiwan","full_name":"Parexel International Co. Ltd.","duties_or_roles":"code 6","organisation_type":"Pharmaceutical company"}

Investigational products

Investigational Product Name
teclistamab
Active Substance
TECLISTAMAB
Modality
Bispecific antibody
Routes Of Administration
SUBCUTANEOUS USE
Route
Subcutaneous
Authorisation Status
prodAuthStatus 1
Investigational Product Name
JNJ-64407564
Active Substance
TALQUETAMAB
Modality
Bispecific antibody
Routes Of Administration
SUBCUTANEOUS USE
Route
Subcutaneous
Authorisation Status
prodAuthStatus 1
Orphan Designation
Yes
Investigational Product Name
DARZALEX 1800 mg solution for injection
Active Substance
DARATUMUMAB
Modality
Monoclonal antibody
Routes Of Administration
SUBCUTANEOUS USE
Route
Subcutaneous
Authorisation Status
prodAuthStatus 2
Orphan Designation
Yes
Starting Dose
1800 mg (product name indicates 1800 mg formulation)
Investigational Product Name
Lenalidomide (various marketed hard capsules)
Active Substance
LENALIDOMIDE
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
Oral
Authorisation Status
prodAuthStatus 2 (marketing authorisation present for listed products)
Dose Levels
5 mg|10 mg|15 mg|25 mg (marketed capsule strengths listed)
Investigational Product Name
Dexamethasone (various tablets)
Active Substance
DEXAMETHASONE
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
Oral
Authorisation Status
prodAuthStatus 2 (marketed products listed)
Dose Levels
2 mg|4 mg|8 mg (marketed tablet strengths listed)
Investigational Product Name
Privigen 100 mg/ml solution for infusion
Active Substance
HUMAN NORMAL IMMUNOGLOBULIN
Modality
Peptide/protein/enzyme
Routes Of Administration
INTRAVENOUS USE
Route
Intravenous
Authorisation Status
prodAuthStatus 2
Combination Treatment
Yes

Related trials

Other published trials that may interest you.